Health News Roundup: TGeneos cancer vaccine shrinks liver tumors in small trial; Trump says he will disclose abortion policy on Monday and more

Long-term data of the drug reinforced the findings that were seen in previous short-term studies, the company said. Geneos cancer vaccine shrinks liver tumors in small trial Nearly a third of patients with advanced liver cancer who received a personalized vaccine developed by Geneos Therapeutics along with an immunotherapy drug in a small, early trial saw their tumors shrink, U.S. researchers reported on Sunday.

Following is a summary of current health news briefs.

Trump says he will disclose abortion policy on Monday

Donald Trump said he would outline his long-awaited policy on abortion on Monday, one that he suggested will be a compromise position with the potential to inflame both sides of the debate. In a post on Truth Social, Trump's social media platform, the Republican presidential candidate said his policy will include exceptions for rape, incest and to protect the life of the mother. While Trump did not provide further details, it seems likely that he will call for a federal ban less restrictive than the six-week prohibition passed in states such as Florida and Georgia.

Bristol Myers' schizophrenia drug reduces symptoms without weight gain in late-stage studies

Bristol Myers Squibb said on Saturday data from late-stage studies of its experimental schizophrenia drug showed it helped reduce symptoms of the disorder without the common side effect of weight gain tied to other antipsychotics. The drugmaker gained access to the treatment, called KarXT, through its $14 billion deal to buy Karuna Therapeutics last year. Long-term data of the drug reinforced the findings that were seen in previous short-term studies, the company said.

Geneos cancer vaccine shrinks liver tumors in small trial

Nearly a third of patients with advanced liver cancer who received a personalized vaccine developed by Geneos Therapeutics along with an immunotherapy drug in a small, early trial saw their tumors shrink, U.S. researchers reported on Sunday. The result was roughly twice the response typically seen with the immunotherapy alone, the researchers said.

(With inputs from agencies.)